Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    VK2809

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Mb-07811, 852948-13-1, Mb07811, Vk-2809, Vk2809, Unii-3z11398fnq
    Molecular Formula
    C28H32ClO5P
    Molecular Weight
    515.0  g/mol
    InChI Key
    LGGPZDRLTDGYSQ-JADSYQMUSA-N
    FDA UNII
    3Z11398FNQ
    VK-2809 is under investigation in clinical trial NCT02927184 (Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease).
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-[[4-[[(2R,4S)-4-(3-chlorophenyl)-2-oxo-1,3,25-dioxaphosphinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-propan-2-ylphenol
    2.1.2 InChI
    InChI=1S/C28H32ClO5P/c1-18(2)25-14-21(8-9-27(25)30)15-26-19(3)12-24(13-20(26)4)32-17-35(31)33-11-10-28(34-35)22-6-5-7-23(29)16-22/h5-9,12-14,16,18,28,30H,10-11,15,17H2,1-4H3/t28-,35+/m0/s1
    2.1.3 InChI Key
    LGGPZDRLTDGYSQ-JADSYQMUSA-N
    2.1.4 Canonical SMILES
    CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OCP3(=O)OCCC(O3)C4=CC(=CC=C4)Cl
    2.1.5 Isomeric SMILES
    CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OC[P@@]3(=O)OCC[C@H](O3)C4=CC(=CC=C4)Cl
    2.2 Other Identifiers
    2.2.1 UNII
    3Z11398FNQ
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 2-((3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy)methyl)-4-(3-chlorophenyl)-2-oxido(1,3,2)dioxaphosphonane

    2. Mb 07811

    3. Mb-07811

    4. Mb07811

    5. Vk2809

    2.3.2 Depositor-Supplied Synonyms

    1. Mb-07811

    2. 852948-13-1

    3. Mb07811

    4. Vk-2809

    5. Vk2809

    6. Unii-3z11398fnq

    7. Chembl457748

    8. 3z11398fnq

    9. Mb-07811 (vk-2809)

    10. 4-[[4-[[(2r,4s)-4-(3-chlorophenyl)-2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-propan-2-ylphenol

    11. (2r,4s)-4-(3-chlorophenyl)-2-((4-(4-hydroxy-3-isopropylbenzyl)-3,5-dimethylphenoxy)methyl)-1,3,2-dioxaphosphinane 2-oxide

    12. Mb 07811

    13. Schembl282796

    14. Gtpl12768

    15. Dtxsid501005783

    16. Ex-a3394

    17. Bdbm50401076

    18. Akos040742104

    19. Db15137

    20. Compound 22c [pmid: 18975928]

    21. Trans-(s)-2-((3,5-dimethyl-4-(4-hydroxy-3-isopropylbenzyl)phenoxy)methyl)-4-(3-chlorophenyl)-2-oxo-(1,3,2)dioxaphosphorinane

    22. Hy-111288

    23. Cs-0034844

    24. Q27258223

    25. (2r,4s)-4-(3-chlorophenyl)-2-((3,5-dimethyl-4-(4-hydroxy-3-isopropylbenzyl)phenoxy)methyl)-2-oxido-(1,3,2)-dioxaphosphonane

    26. 2-((3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy)methyl)-4-(3-chlorophenyl)-2-oxido(1,3,2)dioxaphosphonane

    27. 4-(3-chlorophenyl)-2-[(4-{[4-hydroxy-3-(propan-2-yl)phenyl]methyl}-3,5-dimethylphenoxy)methyl]-1,3,2lambda~5~-dioxaphosphinan-2-one

    2.4 Create Date
    2007-02-21
    3 Chemical and Physical Properties
    Molecular Weight 515.0 g/mol
    Molecular Formula C28H32ClO5P
    XLogP36.9
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count7
    Exact Mass g/mol
    Monoisotopic Mass g/mol
    Topological Polar Surface Area65
    Heavy Atom Count35
    Formal Charge0
    Complexity708
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Investigated for use/treatment in hyperlipidemia.

    5 Pharmacology and Biochemistry
    5.1 Mechanism of Action

    Studies indicate that targeting TR agonists to the liver has the potential to lower both LDL-cholesterol (the "bad" cholesterol) and both hepatic and plasma triglyceride levels.